Novelty Nobility is a private biotech company focused on the research of novel angiogenesis targets and develop antibody-based therapeutics.
Novelty Nobility has raised $16.6M in total funding. The most recent round was Series C. The last funding was announced in November 2024.
Novelty Nobility's investors include HB Investment, SGI Venture Capital, SL Investment, TIPS Program, Shinhan Venture Investment.
Novelty Nobility is headquartered in Seongnam, South Korea.
Novelty Nobility is a private biotech company focused on the research of novel angiogenesis targets and develop antibody-based therapeutics.
Novelty Nobility is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Novelty Nobility — Funding & Investors." VCBacked, November 11, 2024, https://www.vcbacked.co/company/novelty-nobility. Accessed July 19, 2026.
VCBacked. (2024). Novelty Nobility — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/novelty-nobility
{{cite web |title=Novelty Nobility — Funding & Investors |url=https://www.vcbacked.co/company/novelty-nobility |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated